close

Agreements

Date: 2017-09-07

Type of information: Development agreement

Compound: small molecules for the treatment of multiple serious viral infectious diseases

Company: Abivax (France) Evotec (Germany)

Therapeutic area: Infectious diseases

Type agreement: development

Action mechanism: mRNA biogenesis inhibitor

Disease: viral infectious diseases

Details:

  • • On September 7, 2017, Evotec and Abivax announced a strategic collaboration to discover and develop novel treatments for multiple serious viral infectious diseases. Abivax identifies the targets and discover initial drug candidates; Evotec will leverage its industrial state-of-the-art drug discovery platform by optimising Abivax ’s candidates and performing early target development. Targets in respiratory syncitial virus (RSV), influenza and dengue viral infections have already been identified by Abivax  and are being evaluated for further development under the partnership.
  • Abivax ’s antiviral platform is based on its technology of inhibition mRNA biogenesis and its chemical library of more than one thousand small molecules. Abivax  carries out hit identification experiments as well as in vitro and in vivo pharmacology studies. Evotec will drive the medicinal chemistry design and execution, additional pharmacology, ADME (absorption, distribution, metabolism, and excretion), as well as computational chemistry, mode of action and molecular target identification studies.

Financial terms:

  • Financial details were not disclosed. Intellectual property originating from this collaboration and all commercial rights to any drug candidates will be owned by Abivax . This partnership will be supported, in part, by funding from the “Projets de R&D Structurants Pour la Compétitivité” (PSPC) of the “Invest in the Future Program” (PIA), a competitive award granted to Abivax in January 2017. The programme is supervised by the General Commissariat of Investment (Commissariat Général de l’Investissement) and operated by Bpifrance.

Latest news:

Is general: Yes